Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
68.41 USD | -0.20% | +1.74% | -4.48% |
May. 16 | Transcript : Intra-Cellular Therapies, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 09:20 AM | |
May. 07 | Sector Update: Health Care Stocks Steady Pre-Bell Tuesday | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-4.48% | 7.22B | D+ | ||
+0.82% | 91.94B | A- | ||
-1.32% | 38.74B | A- | ||
-12.88% | 32.82B | B- | ||
+64.13% | 26.66B | A | ||
-16.31% | 15.32B | C | ||
-11.38% | 11.65B | D+ | ||
+173.10% | 10.37B | D | ||
-49.84% | 10.12B | B | ||
+3.60% | 9.06B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ITCI Stock
- Ratings Intra-Cellular Therapies, Inc.